
Cognito Therapeutics partnered with the Rhode Island Life Science Hub to launch a statewide Brain Health Collaboratory evaluating its Spectris platform for Alzheimer's disease. It is Cognito's third such partnership, with pivotal HOPE trial results expected later in 2026.
Cognito Therapeutics presented new biomarker data from its Phase 2 study at the Alzheimer's Association International Conference. The findings show that daily use of Spectris, its non-invasive sensory stimulation headset, increased cerebrospinal fluid levels of several HDL-like lipid transport proteins in patients with amyloid-positive mild cognitive impairment. The company reads the data as a coordinated biological response. The data are exploratory but reinforce a proposed mechanism for the gamma-frequency approach. A full data readout is expected next month.